Expand BMEA Menu
BMEA MENU

BMEA Latest Press Releases

-- January 13, 2025 --

Biomea Fusion to Become a Diabetes & Obesity Medicines Company Globe Newswire 9:00 AM

-- January 7, 2025 --

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study Globe Newswire 9:00 AM

-- January 6, 2025 --

Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference Globe Newswire 7:00 AM

-- December 17, 2024 --

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes Globe Newswire 8:10 AM

-- December 16, 2024 --

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D) Globe Newswire 6:15 PM

-- December 12, 2024 --

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) Globe Newswire 5:02 PM

-- December 9, 2024 --

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia Globe Newswire 4:01 PM

-- December 6, 2024 --

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia Globe Newswire 8:00 AM

-- December 2, 2024 --

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- November 18, 2024 --

Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024) Globe Newswire 8:00 AM

-- November 1, 2024 --

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- October 30, 2024 --

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate Globe Newswire 4:00 PM

-- October 29, 2024 --

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights Globe Newswire 4:46 PM

-- October 21, 2024 --

Biomea Fusion Announces Approval of "icovamenib" as International Nonproprietary Name for BMF-219 Globe Newswire 9:00 AM

-- October 15, 2024 --

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy Globe Newswire 4:05 PM

-- October 7, 2024 --

Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024) Globe Newswire 9:00 AM

-- October 1, 2024 --

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts Globe Newswire 9:00 AM

-- September 26, 2024 --

FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials Globe Newswire 2:00 PM